European society of contraception statement on contraception in obese women.
The obesity 'epidemic' continues to increase, mostly but not only in developed countries. As overweight and obese women are at an increased risk for venous thromboembolism (VTE) at baseline and at a much higher risk during pregnancy, it is essential to help these women to plan pregnancies carefully and to use contraceptives with a positive ratio of benefits versus risks. The Expert Group on hormonal and molecular contraception of the European Society of Contraception convened to review the existing evidence and propose recommendations to the prescribers in line with most recent studies and with the Medical Eligibility Criteria of the World Health Organisation.
* Department for Reproductive Endocrinology, Clinic of Gynecology and Obstetrics, University Hospital Zürich , Switzerland.
Gabriele S
GS
Merki-Feld
Sven
S
Skouby
David
D
Serfaty
Medard
M
Lech
Johannes
J
Bitzer
Pier Giorgio
PG
Crosignani
Angelo
A
Cagnacci
Regine
R
Sitruk-Ware
D003267:Contraception / Q000009:adverse effects / Q000379:methods; D044363:Contraception, Postcoital; D003271:Contraceptive Agents, Female / Q000009:adverse effects / Q000493:pharmacokinetics; D019049:Developed Countries; D005060:Europe; D005260:Female; D006801:Humans; D007436:Intrauterine Devices, Medicated / Q000009:adverse effects; D009765:Obesity / Q000378:metabolism; D050177:Overweight; D011247:Pregnancy; D012955:Societies, Medical; D054556:Venous Thromboembolism / Q000139:chemically induced
D003271:Contraceptive Agents, Female
Contraceptive failure; Depo-medroxyprogesterone; Efficacy; Hormonal contraception; Obesity; Progestin-only contraception; Thromboembolic risk; Weight